Cell Genesys, Inc. (CEGE) Receives Expected FDA Halt on Clinical Prostate Cancer
Cell Genesys (Nasdaq:CEGE) focuses on the development and commercialization of novel biological therapies for patients with cancer. The company's lead product platform, GVAX immunotherapy for cancer, holds the potential to treat multiple types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer. The company today announced that the U.S. Food and Drug Administration has placed an expected partial clinical hold on GVAX's phase 3 program. The halt follows the company’s August 27, 2008 announcement which stated it would end the VITAL-2 phase 3 trial for GVAX. Cell Genesys terminated the trial after its Independent Data Monitoring Committee (IDMC)…